WMCHealth is the third-highest enrolling site nationally for study finding that patients receiving GammaTile® therapy experienced a greater than 50% reduction in the risk of recurrence or death, and two-year overall survival rates that doubled.
WMC’s trial participation reflects its ongoing focus on expanding access to advanced cancer care, clinical trials, and multidisciplinary treatment options for patients with complex brain tumors.
VALHALLA, NY — June 18, 2026 — Westchester Medical Center (WMC), the flagship academic medical center of the Westchester Medical Center Health Network (WMCHealth), today highlighted results from the Phase III ROADS clinical trial, a multicenter randomized study evaluating GammaTile® therapy for patients undergoing surgery for newly diagnosed brain metastases. The trial found that patients who received surgery with GammaTile therapy demonstrated superior tumor control and lived longer without recurrence compared to the current standard of care.
Led by Principal Investigator Simon Hanft, MD, Chief of Neurosurgical Oncology at WMCHealth, WMC was the third-highest enrolling site nationally, with 20 patients included in the study that included 230 enrolled patients across 32 centers. The ROADS trial compared GammaTile, a collagen tile-based radiation therapy embedded with cesium-131 radiation sources provided immediately after tumor removal surgery, with postoperative stereotactic radiation therapy (SRT), the current standard of care. This innovative approach addresses a gap in conventional care where patients typically must wait weeks between surgery and radiation therapy.
“At WMCHealth, we are committed to bringing the latest advances in medicine to patients here in Westchester and across the Hudson Valley,” said David Lubarsky, MD, MBA, FASA, President and CEO of WMCHealth. “Through our participation in the ROADS trial, we are helping expand access to leading-edge treatment options and offering more hope to those impacted by brain cancer.”
GammaTile therapy is designed to deliver targeted radiation at the time of surgery, when residual tumor burden may be lowest, while reducing the traditional delay between surgery and postoperative radiation therapy.
Key findings from the trial, which were presented as a late-breaking presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract #LBA2000), included:
- Patients receiving GammaTile experienced a greater than 50% reduction in the risk of recurrence or death.
- Two-year overall survival improved from 35.7% with standard treatment to 61.7% among patients receiving GammaTile.
- Surgical bed recurrence at one year was reduced from 11.9% with standard therapy to just 1.0% with GammaTile.
- These benefits were achieved without increased toxicity, radiation necrosis, or declines in quality of life.
WMC’s participation in the ROADS trial reflects its ongoing focus on expanding access to advanced cancer care, clinical trials, and multidisciplinary treatment options for patients with complex brain tumors. The study brought together neurosurgeons, radiation oncologists, research coordinators, physicists, and clinical trial specialists across participating sites to evaluate an approach that may inform future care for patients with operable brain metastases.
As the region’s academic medical center and a referral center for complex neurosurgical care, WMCHealth continue to strengthen programs that connect patients to advanced technologies, clinical research, and coordinated care for primary and metastatic brain tumors.
# # #